RevolutionEHR integrates with AMD iManager

Article

The integration will allow RevolutionEHR practices to simply and reduce data entry.

Madison, WI-RevolutionEHR announces that it is integrating AMD iManager to improve workflow and reduce duplicate data entry for offices utilizing both solutions. AMD iManager is a fully automated age-related macular degeneration (AMD) patient management suite that provides customers patient data extraction, identification and education to efficiently manage, monitor and treat patients at risk for AMD.

The software integration will enable RevolutionEHR practices to simplify the implementation process of incorporating AMD iManager into their practices, and reduce duplication of data entry between the two systems.

"One of the main goals of RevolutionEHR is to help our doctors help their patients,” says Scott Jens, OD, FAAO, chief executive officer of RevolutionEHR. “It's rare that a partnership allows us for such ease in achieving that goal and we are thrilled to work with the iManager team to assist our doctors with streamlined patient care .”

RevolutionEHR’s cloud-based architecture enables integrations with add-on solutions such as AMD iManager. The ability to connect additional offerings to RevolutionEHR through web services interfaces can improve office workflow.

 

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.